金双歧辅助治疗新生儿高胆红素血症疗效的Meta分析

目的对金双歧治疗新生儿高胆红素血症(NHBE)的辅助作用进行系统评价,为临床实践提供依据。方法计算机联机检索中国知网、维普、万方数据库(各数据库检索时间为创建至2017年3月)中关于金双歧辅助治疗NHBE的随机对照试验(RCT),用RevMan 5.3软件对数据进行Meta分析。结果共纳入6篇RCT,包括494例患儿。Meta分析结果显示:金双歧辅助治疗NHBE后胆红素值低于对照组,差异有统计学意义MD=-18.72,95%CI(-20.47,-16.97),P0.00001];金双歧组胆红素消退至正常值需要的时间小于对照组,差异有统计学意义MD=-1.41,95%CI(-1.61,-1.21),P0.00001]。结论 Meta分析结果支持金双歧辅助治疗NHBE,建议开展更加科学设计,更加严谨执行的多中心大样本临床试验。基于现有临床证据,金双歧辅助治疗NHBE有效,但本结论尚需要进行高质量临床RCT研究予以证实。

Adjuvant therapy of neonatal hyperbilirubinemia with Golden Bifid: A meta analysis

Abstract: Objective To systematically evaluate the effect of Golden Bifid as the adjuvant therapy of neonatal hyperbilirubinemia (NHBE), and provide reference for clinical practice. Methods CNKI, VIP and Wanfang Data were searched (the time period of data retrieval was from the creation of the database to March 2017) for the articles about randomized controlled trials (RCTs) on Golden Bifid as the adjuvant therapy for NHBE. RevMan 5.3 software was used for meta analysis. Results 6 RCTs involving 494 cases were included. Meta analysis showed that the level of bilirubin after treatment with Golden Bifid was significantly lower than that in the control group MD=-18.72, 95%CI (-20.47, -16.97), P<0.00001]. The time to recovery of normal bilirubin level in Golden Bifid group was shorter than in the control group, with statistically significant difference MD=-1.41, 95%CI (-1.61, -1.21), P<0.00001]. Conclusion Based on existing clinical evidences and this meta analysis, Golden Bifid is effective as the adjuvant therapy for NHBE, although this conclusion needs to be further confirmed by more high-quality RCTs.